{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:19:03Z","timestamp":1786997943603,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.12.016","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T08:57:58Z","timestamp":1578301078000},"page":"1345-1351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-202X","authenticated-orcid":false,"given":"Madleen","family":"Orumaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne K.","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dehlendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Olaug","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo T.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0818-9752","authenticated-orcid":false,"given":"Suzanne","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4100-4855","authenticated-orcid":false,"given":"Mari","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.016_b0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.vaccine.2019.12.016_b0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bpobgyn.2017.08.006","article-title":"Epidemiology and burden of HPV-related disease","volume":"47","author":"Serrano","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.vaccine.2019.12.016_b0015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0020","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/MLG.0b013e31816a7135","article-title":"Recurrent respiratory papillomatosis: a review","volume":"118","author":"Derkay","year":"2008","journal-title":"Laryngoscope"},{"key":"10.1016\/j.vaccine.2019.12.016_b0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/427557","article-title":"Development and duration of human papillomavirus lesions, after initial infection","volume":"191","author":"Winer","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0030","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/522863","article-title":"The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries","volume":"196","author":"Kjaer","year":"2007","journal-title":"J Infect Dis"},{"issue":"Suppl 8","key":"10.1016\/j.vaccine.2019.12.016_b0035","doi-asserted-by":"crossref","first-page":"S849","DOI":"10.1093\/cid\/civ813","article-title":"Human papillomavirus and genital warts: a review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines","volume":"61","author":"Park","year":"2015","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2019.12.016_b0040","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1086\/342109","article-title":"External genital warts: diagnosis, treatment, and prevention","volume":"35","author":"Wiley","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12325-015-0178-4","article-title":"Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review","volume":"32","author":"Mariani","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2019.12.016_b0050","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nygard","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.12.016_b0055","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"131","author":"Guan","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2019.12.016_b0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2019.12.016_b0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0070","series-title":"A guide to essential practice","article-title":"Comprehensive cervical cancer control","author":"WHO","year":"2014"},{"key":"10.1016\/j.vaccine.2019.12.016_b0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/infdis\/jiv368","article-title":"Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs","volume":"213","author":"Elfstrom","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0080","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/OLQ.0000000000000418","article-title":"Significant reduction in the incidence of genital warts in young men 5 years into the Danish human papillomavirus vaccination program for girls and women","volume":"43","author":"Bollerup","year":"2016","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0085","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/cid\/cit436","article-title":"Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark","volume":"57","author":"Blomberg","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0090","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/infdis\/jis405","article-title":"Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability","volume":"206","author":"Leval","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0095","series-title":"Essential medical statistics","author":"Kirkwood","year":"2003"},{"key":"10.1016\/j.vaccine.2019.12.016_b0100","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.12.016_b0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries","volume":"66","author":"Kjaer","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ypmed.2010.03.014","article-title":"Early smoking initiation, sexual behavior and reproductive health \u2013 a large population-based study of Nordic women","volume":"51","author":"Hansen","year":"2010","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2019.12.016_b0115","doi-asserted-by":"crossref","first-page":"e88323","DOI":"10.1371\/journal.pone.0088323","article-title":"Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance","volume":"9","author":"Nygard","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.12.016_b0120","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/aogs.13088","article-title":"Contraceptive non-use and emergency contraceptive use at first sexual intercourse among nearly 12 000 Scandinavian women","volume":"96","author":"Guleria","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.vaccine.2019.12.016_b0125","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/GCO.0000000000000208","article-title":"Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination","volume":"27","author":"Lehtinen","year":"2015","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2019.12.016_b0130","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/ijc.31119","article-title":"Impact of gender-neutral or girls-only vaccination against human papillomavirus-results of a community-randomized clinical trial (I)","volume":"142","author":"Lehtinen","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2019.12.016_b0135","series-title":"Blood borne and sexually transmitted diseases in Norway 2016","author":"Annual report","year":"2017"},{"key":"10.1016\/j.vaccine.2019.12.016_b0140","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10508-009-9494-6","article-title":"Analysis of first coitus","volume":"39","author":"Stigum","year":"2010","journal-title":"Arch Sex Behav"},{"key":"10.1016\/j.vaccine.2019.12.016_b0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/OLQ.0000000000000231","article-title":"Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States","volume":"42","author":"Liu","year":"2015","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0150","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/jmv.24968","article-title":"The early impact of human papillomavirus vaccination on anogenital warts in Quebec, Canada","volume":"90","author":"Steben","year":"2018","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2019.12.016_b0155","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/OLQ.0b013e31827bd66b","article-title":"Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program","volume":"40","author":"Baandrup","year":"2013","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0160","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.016_b0165","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/sextrans-2014-051813","article-title":"Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme","volume":"91","author":"Chow","year":"2015","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2019.12.016_b0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0175","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jinf.2017.01.007","article-title":"No evidence for cross-protection of the HPV-16\/18 vaccine against HPV-6\/11 positivity in female STI clinic visitors","volume":"74","author":"Woestenberg","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2019.12.016_b0180","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1186\/1471-2458-14-867","article-title":"HPV catch-up vaccination of young women: a systematic review and meta-analysis","volume":"14","author":"Couto","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2019.12.016_b0185","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/infdis\/jiu413","article-title":"Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway","volume":"211","author":"Burger","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0190","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/infdis\/jix476","article-title":"The impact of human papillomavirus catch-up vaccination in australia: implications for introduction of multiple age cohort vaccination and postvaccination data interpretation","volume":"216","author":"Drolet","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.016_b0195","doi-asserted-by":"crossref","first-page":"e019005","DOI":"10.1136\/bmjopen-2017-019005","article-title":"Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: a registry-based study in Norway","volume":"8","author":"Hansen","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2019.12.016_b0200","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1403494816653669","article-title":"Burden and incidence of human papillomavirus-associated cancers and precancerous lesions in Denmark","volume":"44","author":"Svahn","year":"2016","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.vaccine.2019.12.016_b0205","first-page":"915","article-title":"Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program","volume":"25","author":"Baldur-Felskov","year":"2014","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.vaccine.2019.12.016_b0210","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2019.12.016_b0215","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cam4.1961","article-title":"Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-potential for prevention","volume":"8","author":"Dovey de la Cour","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.vaccine.2019.12.016_b0220","series-title":"Draft: global strategy towards the elimination of cervical cancer as a public health problem","author":"WHO: Expert Group on Cervical Cancer Elimination","year":"2019"},{"key":"10.1016\/j.vaccine.2019.12.016_b0225","unstructured":"Pan American Health Organization. Update on the Supply of HPV Vaccine & Proposed Actions [Powerpoint slides]. 2019. Available from: https:\/\/www.paho.org\/hq\/index.php?option=com_docman&view=download&slug=update-on-the-supply-of-hpv-vaccine-and-proposed-actions-fitzsimmons-paho&Itemid=270&lang=es."},{"key":"10.1016\/j.vaccine.2019.12.016_b0230","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.virusres.2016.11.020","article-title":"Developments in L2-based human papillomavirus (HPV) vaccines","volume":"231","author":"Schellenbacher","year":"2017","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2019.12.016_b0235","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1016\/j.vaccine.2016.07.051","article-title":"Immunogenicity of next-generation HPV vaccines in non-human primates: measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine","volume":"34","author":"Gupta","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.016_b0240","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S1470-2045(14)71179-9","article-title":"Next generation prophylactic human papillomavirus vaccines","volume":"16","author":"Schiller","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2019.12.016_b0245","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.12.016_b0250","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"46","key":"10.1016\/j.vaccine.2019.12.016_b0255","article-title":"Data resource profile: The Danish national prescription registry","author":"Pottegard","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.12.016_b0260","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish national prescription registry","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.vaccine.2019.12.016_b0265","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1403494810394718","article-title":"The Danish national health service register","volume":"39","author":"Andersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.vaccine.2019.12.016_b0270","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/sti.2010.044412","article-title":"Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11","volume":"87","author":"Brisson","year":"2011","journal-title":"Sex Transm Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:38:05Z","timestamp":1759401485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19316585"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}